QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RZLT

QT78Rezolute, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
5.02
+0.23+4.80%
OverviewShort InterestFilings
RZLTQT78Rezolute, Inc.·NASDAQ
OverviewShort InterestFilings
5.02+4.80%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand96.29M
Perf Week30.05%
Market Cap461.24MForward P/E-EPS next Y-0.65Insider Trans0.01%Shs Float-Perf Month61.94%
Enterprise Value451.12MPEG-EPS next Q-0.13Inst Own-Short Float-Perf Quarter103.24%
Income-75412759.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y148.51%
Sales-P/B4.27EPS next Y7.06%ROA-64.95%Short Interest-Perf YTD112.71%
Book/sh1.33P/C-EPS next 5Y-ROE-58.82%52W High11.46 -56.20%Perf Year21.55%
Cash/sh1.38P/FCF-EPS past 3/5Y-ROIC-73.68%52W Low1.07 369.16%Perf 3Y-
Dividend Est.-EV/EBITDA-5.54Sales past 3/5Y-Gross Margin0.00%Volatility6.35% 6.26%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM30.08%Oper. Margin0.00%ATR (14)0.35Perf 10Y-
Dividend Ex-Date-Quick Ratio15.84Sales Y/Y TTM-Profit Margin0.00%RSI (14)74.26Recom2.00
Dividend Gr. 3/5Y-Current Ratio15.84EPS Q/Q0.00%SMA2026.94%Beta0.92Target Price8.67
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5040.66%Rel Volume1.66Prev Close4.79
Employees64LT Debt/Eq0.01EarningsSep 16SMA200-3.75%Avg Volume1.69MPrice5.02
IPO DateJan 14, 2013Option/ShortYes / YesEPS/Sales Surpr.-37.50% -Net Debt/EBITDA0.12Volume2,811,985Change4.80%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-03-26ReiteratedWedbushOutperform$2.00 → $6.00
Jun-03-26UpgradeCitizensMarket Perform → Market Outperform
Jun-02-26ReiteratedBTIGBuy$5.00 → $6.00
May-14-26ReiteratedMaxim GroupBuy$4.00 → $10
Mar-25-26UpgradeWedbushNeutral → Outperform
Jan-08-26ReiteratedWedbushNeutral$1.00 → $2.00
Dec-12-25ReiteratedMaxim GroupBuy$20 → $4.00
Dec-12-25ReiteratedH.C. Wainwright$14 → $5.00
Dec-11-25ReiteratedCraig-Hallum$14 → $2.00
Dec-11-25ReiteratedBTIGBuy$17 → $5.00
Latest News
Jun-17-26
Jun-17-2607:15AM
Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug ProgramBenzinga
Jun-15-26
Jun-15-2611:12AM
Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
FY 2018
6/30/2018
FY 2017
6/30/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit000
Selling, General and Administrative Excl. Other181512
Research and Development625644
Other Operating Expense0-10
Operating Income-80-70-56
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-5-2-4
Net Income Before Taxes-74-68-52
Income Taxes
000
Consolidated Net Income-74-68-52
Net Income From Continuing Operations-74-68-52
Net Income-74-68-52
EPS (Recurring)-0.98-1.33-1.01
EPS (Basic, Before Extraordinaries)-0.98-1.33-1.01
EPS (Diluted)-0.98-1.33-1.01
EBITDA-74-68-52
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding765151
Market Capitalization339——
Operating Lease Expense
———
Insider Trading Volume
$5.44$4.77$4.10$3.42$2.75● Close Price0.00M1.01M2.02M3.03M4.04MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Evans DaronCFOMar 30 '26Buy2.8510,00028,500414,462Mar 31 12:00 AM
Hogenhuis WladimirDirectorDec 16 '25Buy1.695,6509,549119,675Dec 17 12:00 AM
ROBERTS BRIAN KENNETHChief Medical OfficerDec 16 '25Buy1.7028,00047,600308,352Dec 17 12:00 AM
Evans DaronCFODec 15 '25Buy1.7745,00079,578415,900Dec 15 12:00 AM
Elam Nevan CCEODec 15 '25Buy1.5932,00050,880641,119Dec 15 12:00 AM
Karnawat Sunil RatilalChief Commercial OfficerDec 15 '25Buy1.6212,10019,59971,542Dec 15 12:00 AM
ROBERTS BRIAN KENNETHChief Medical OfficerJun 25 '25Buy4.382,50010,93915,500Jun 26 12:00 AM
Evans DaronCFOJun 24 '25Buy4.055,00020,250268,900Jun 24 12:00 AM
Kim Young-JinDirectorJun 13 '25Buy3.251,230,7693,999,9998,423,386Jun 23 12:00 AM
KREHER NERISSADirectorJun 13 '25Buy3.253,0769,99737,576Jun 23 12:00 AM
Hogenhuis WladimirDirectorMar 31 '25Buy2.926,75819,73384,025Apr 01 12:00 AM
Elam Nevan CCEOMar 27 '25Buy2.8512,30234,999224,119Mar 31 12:00 AM
Evans DaronCFOMar 26 '25Buy2.8820,00057,700237,900Mar 28 12:00 AM
Hogenhuis WladimirDirectorFeb 18 '25Buy4.7010,00047,00077,267Feb 20 12:00 AM
Kim Young-JinDirectorJun 25 '24Buy4.001,250,0005,000,0007,192,617Feb 19 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR